Galarza-Muñoz Gaddiel, Briggs Farren B S, Evsyukova Irina, Schott-Lerner Geraldine, Kennedy Edward M, Nyanhete Tinashe, Wang Liuyang, Bergamaschi Laura, Widen Steven G, Tomaras Georgia D, Ko Dennis C, Bradrick Shelton S, Barcellos Lisa F, Gregory Simon G, Garcia-Blanco Mariano A
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA; Center for RNA Biology, Duke University, Durham, NC 27710, USA; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
Cell. 2017 Mar 23;169(1):72-84.e13. doi: 10.1016/j.cell.2017.03.007.
Multiple sclerosis (MS) is an autoimmune disorder where T cells attack neurons in the central nervous system (CNS) leading to demyelination and neurological deficits. A driver of increased MS risk is the soluble form of the interleukin-7 receptor alpha chain gene (sIL7R) produced by alternative splicing of IL7R exon 6. Here, we identified the RNA helicase DDX39B as a potent activator of this exon and consequently a repressor of sIL7R, and we found strong genetic association of DDX39B with MS risk. Indeed, we showed that a genetic variant in the 5' UTR of DDX39B reduces translation of DDX39B mRNAs and increases MS risk. Importantly, this DDX39B variant showed strong genetic and functional epistasis with allelic variants in IL7R exon 6. This study establishes the occurrence of biological epistasis in humans and provides mechanistic insight into the regulation of IL7R exon 6 splicing and its impact on MS risk.
多发性硬化症(MS)是一种自身免疫性疾病,其中T细胞攻击中枢神经系统(CNS)中的神经元,导致脱髓鞘和神经功能缺损。MS风险增加的一个驱动因素是由IL7R外显子6的可变剪接产生的白细胞介素-7受体α链基因的可溶性形式(sIL7R)。在这里,我们鉴定出RNA解旋酶DDX39B是该外显子的有效激活剂,因此是sIL7R的抑制剂,并且我们发现DDX39B与MS风险有很强的遗传关联。事实上,我们表明DDX39B 5'UTR中的一个基因变体减少了DDX39B mRNA的翻译并增加了MS风险。重要的是,该DDX39B变体与IL7R外显子6中的等位基因变体表现出很强的遗传和功能上位性。这项研究确定了人类中生物上位性的发生,并为IL7R外显子6剪接的调控及其对MS风险的影响提供了机制性见解。